menu
    • menu
    [{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Laboratorios Poen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Laboratorios Poen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Laboratorios Poen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"L-Arginine","moa":"Cationic amino acid transporter 3; Antizyme inhibitor 2; Argininosuccinate lyase; Nitric oxide synthase, inducible; High affinity cationic amino acid transporter 1; Arginase-2, mitochondrial; Cationic amino acid transporter 4; Argininosuccinate synthase; Nitric oxide synthase 3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"BRAZIL","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Megalabs \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Megalabs

    Menu

    Megalabs

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 08, 2024

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palbociclib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : Palbociclib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomalidomide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pilot Bioequivalence Study of Pomalidomide

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 28, 2023

                            Lead Product(s) : Pomalidomide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laboratorios Poen

                            Argentina arrow
                            Coatings Trends
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 12, 2023

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-Arginine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Megalabs USA Announces Launch of Two New Products in North American Market: Abintra and Glutapak R

                            Details : Abintra features a unique combination of arginine, glutamine, high-quality protein, and antioxidant vitamins and minerals in a quick-dissolving powder. The formula works to promote tissue synthesis and wound healing from within.

                            Product Name : Abintra

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            August 24, 2022

                            Lead Product(s) : L-Arginine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgrastim

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : Filgrastim

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 08, 2021

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed

                            Megalabs

                            Brazil arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Pegfilgastim Amgen

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 05, 2021

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Laboratorios Poen

                            Argentina arrow
                            Coatings Trends
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bepotastine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 01, 2021

                            Lead Product(s) : Bepotastine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Laboratorios Poen

                            Argentina arrow
                            Coatings Trends
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difluprednate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Sur...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : Difluprednate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth